1. Home
  2. NNDM vs LYEL Comparison

NNDM vs LYEL Comparison

Compare NNDM & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nano Dimension Ltd.

NNDM

Nano Dimension Ltd.

N/A

Current Price

$1.55

Market Cap

322.1M

Sector

Technology

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$10.80

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NNDM
LYEL
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
322.1M
320.1M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
NNDM
LYEL
Price
$1.55
$10.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
1.6M
84.8K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$102,437,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
77.30
N/A
52 Week Low
$1.19
$11.47
52 Week High
$2.32
$45.00

Technical Indicators

Market Signals
Indicator
NNDM
LYEL
Relative Strength Index (RSI) 47.53 28.50
Support Level $1.50 N/A
Resistance Level $1.58 $15.38
Average True Range (ATR) 0.05 0.80
MACD -0.01 -0.44
Stochastic Oscillator 33.33 5.88

Price Performance

Historical Comparison
NNDM
LYEL

About NNDM Nano Dimension Ltd.

Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: